R&D Spending Showdown: Johnson & Johnson vs Dr. Reddy's Laboratories Limited

Pharma Giants' R&D Spending: A Decade of Innovation

__timestampDr. Reddy's Laboratories LimitedJohnson & Johnson
Wednesday, January 1, 2014124020000008494000000
Thursday, January 1, 2015174490000009046000000
Friday, January 1, 2016178340000009095000000
Sunday, January 1, 20171955100000010554000000
Monday, January 1, 20181826500000010775000000
Tuesday, January 1, 20191560700000011355000000
Wednesday, January 1, 20201541000000012340000000
Friday, January 1, 20211654100000014277000000
Saturday, January 1, 20221748200000014135000000
Sunday, January 1, 20231938100000015048000000
Monday, January 1, 20242287300000017232000000
Loading chart...

Cracking the code

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Johnson & Johnson and Dr. Reddy's Laboratories Limited have been at the forefront of this race.

Johnson & Johnson: A Steady Climb

From 2014 to 2023, Johnson & Johnson's R&D expenses have shown a consistent upward trend, peaking in 2023 with a 77% increase from 2014. This steady climb underscores their dedication to pioneering new treatments and technologies.

Dr. Reddy's Laboratories: A Surge in Investment

Dr. Reddy's Laboratories, on the other hand, has demonstrated a more volatile yet aggressive approach. Their R&D spending surged by 84% from 2014 to 2024, reflecting a strategic push towards expanding their global footprint.

The Missing Year

While 2024 data for Johnson & Johnson is unavailable, Dr. Reddy's continued their upward trajectory, hinting at a potential shift in the competitive landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025